Veana Therapuetics (Veana) is a clinical-stage biopharmaceutical company focused on the development of a novel oral pill designed to target cancer cells, while sparing normal cells, in women with intractable breast cancer. Their lead compound, VT-101, is a novel oral small molecule that works by destabilizing mitochondria, thereby inducing both apoptotic and immunogenic cell death. In a Phase 1 clinical trial involving 17 patients with Stage III-IV cancer, VT-101 demonstrated a robust safety profile. It is currently being evaluated in an ongoing dose-escalation Phase 1b trial for metastatic HER2+ breast cancer patients who have not responded to existing treatments. Preliminary results have shown promising potential effectiveness.

Veana is planning further investigations into the potential of their compound in treating triple-negative breast cancer (TNBC). Additionally, they are exploring the possibility of its application in other types of cancer.



Series Seed-2A
Funded 2024


Breast Cancer


Therapies & Management


Early data, during safety studies, showed that the Veana oral pill effectively stabilized the disease in advanced cancer patients for 9 months with little or no side effects other than in patients with a history of atrial fibrillation, thus effectively extending the survival of such patients. Oral medicines for advanced breast cancer patients may offer an alternative treatment for previously untreatable cases. Destabilizing mitochondrial cells potentially can be a broad mechanism of action allowing additional safe and effective treatment for other cancers.

Press Release